Physician profile
Mohammad A Bashir
NPI 1659306843
$618.24
in general payments reported to CMS, 2019-2025
11 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.10 · 2020: $43.64 · 2023: $74.44 · 2024: $244 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527 · Travel and Lodging: $26.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.70 |
| Travel and Lodging | $26.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $238.92 | 2023-2025 | |
| Amgen INC. | $118.31 | 2019-2025 | Tavneos, Krystexxa |
| Apellis Pharmaceuticals, INC. | $47.23 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $35.36 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.30 | 2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $30.15 | 2025 | Keveyis |
| Calliditas Therapeutics US INC. | $26.35 | 2025 | Tarpeyo |
| Cormedix INC. | $24.95 | 2024 | Defencath |
| Astrazeneca Pharmaceuticals LP | $22.26 | 2020 | |
| Alnylam Pharmaceuticals INC. | $22.03 | 2023 | Amvuttra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.